QAdvis is now Aurevia

Two years ago, QAdvis became part of something bigger. At first, the change was mostly visible on paper — a new owner and later a new name: Aurevia. But this wa...

Diamyd Medical fyller på kassan och slutför rekrytering i fas III-studie

Diabetesforskningsbolaget Diamyd Medical har genomfört en riktad emission av cirka 17,2 miljoner B-aktier till kursen 13,54 kronor och tillförs därmed cirka 233...

Hansa Biopharma secures billion deal: “Profitability within reach”

Lund-based Hansa Biopharma is raising more than SEK 1bn through a new licensing agreement for its in-house developed transplant drug imlifidase.

GSK eyes blockbuster potential – plans five new trials

GSK sees blockbuster potential in its experimental drug candidate Mo-rez. Early trial results suggest the treatment may shrink tumours in patients with advanced...

A tiny animal with great importance

From the mythical Ganges River to the less sacred, but considerably cleaner waters in KI's aquariums in Solna. The little zebrafish has made an unconscious care...

Integrated solutions for liquid handling

Greater efficiency for manufacturers in laboratory automation and many other industries

Multicancer test failed to meet its goal – shares plunged

A blood test designed to detect multiple types of cancer failed to meet its primary endpoint in a large UK study. The company behind the test saw its market value cut in half.

Will the FDA’s new transparency policy extend to medical devices? (Part 1)

In a significant policy shift, the FDA has begun publishing Complete Response Letters (CRLs) for drug and biologic applications that were initially rejected but...

Top 10 biggest drug launches 2026

Two presumed sales rockets – both in obesity and type 2 diabetes – top a list of potential blockbusters expected to launch in the United States in 2026.

Samuel Lagercrantz: ”Obesity, blockbusters and Swedish biotech”

The development of technologies to bypass the blood-brain barrier is particularly exciting right now, as it holds the potential to unlock new treatments for a r...

Obesity dominates as future blockbusters are identified

Two drug candidates targeting obesity and diabetes stand out sharply in Clarivate’s newly selected “starting eleven” of potential future blockbusters worth watching.

“The US matters most – even in times of turbulence”

Tariffs, geopolitical uncertainty and rapidly changing trade conditions mean that Swedish life science companies need more routes into global markets – and fast...

Nordic collaboration delivering the next leap in spatial biology

Spatial biology is reshaping how researchers understand complex tissue environments, from tumour–immune interactions to treatment response. A major barrier has ...

“We develop vaccines no one else is developing”

Vaccines delivered via patches rather than injections. Future solutions could fundamentally reshape global health. Meet the man leading efforts to distribute va...

Product demo with features, software and best-practices

Get interesting insights about ZEISS O-INSPECT duo in our demo recording.

Bio-Works

JMP Statistical Discovery

BMS and venture capital giant form new company

The American pharmaceutical company Bristol Myers Squibb, together with the venture capital firm Bain Capital, is forming a new biotech company. The company wil...

Björn Arvidsson will lead research and innovation in Region Uppsala

The Swedish life science profile Björn Arvidsson has been appointed Director of Research and Innovation for Region Uppsala.

Are you ready for EMC 2024?

Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.

Immedica högt på listan över Sveriges bästa arbetsplatser

Stockholmsbaserade Immedica Pharma hamnar tvåa på listan över Sveriges bästa arbetsplatser i kategorin medelstora organisationer. Även andra läkemedelsföretag f...

Webinar: Can AI replace humans in pharmacovigilance?

The webinar will explore how AI can transform pharmacovigilance by enhancing efficiency, reducing errors, and addressing challenges such as software costs, data...

Southern Swedish company Aqilion develops drug for eosinophilic esophagitis

When Aqilion began developing a drug for eosinophilic esophagitis, the molecule was classified as an orphan drug. But the prevalence of the disease now appears ...

Gothenburg-based Anyo Labs gains ground in the AI race

In a fifty-square-metre space in Gothenburg sits a company aiming to secure its place on one of the world's hottest technological stages: AI-driven drug develop...